Thomas, McNerney and The Vertical Group have led a $52 million venture round for Israel's Galil Medical. Galil Medical develops and markets a cryotherapy platform that uses freezing technology and proprietary needle design for treating prostate and kidney cancer as well as other conditions. Galil has more than $20 million in annual revenue.
"We are now well positioned both organizationally and financially, to expand our global sales and marketing activities as well as to invest in R&D and clinical programs required to support existing and new applications for our cryotherapy technology," says CEO Chen Barir.
- read the release on the round